John Marren takes NOVAVAX risk management role
NOVAVAX, a Maryland-based business producing next-generation vaccines, has appointed John Marren as senior director for global risk and insurance management.
Marren joins with more than three decades’ experience in risk management. Starting as a loss prevention consultant with Factory Mutual Engineering Corporation, he then spent almost a decade at Marsh, where he was vice president.
He has significant experience managing captives, both with Geneva-based fragrance manufacturer Firmenich, and for chemical group Henkel of America, where he served as director of its Barbados-domiciled chemical industry group captive, Primex.
Until 2021, Marren has a senior director for global risk and insurance manager with biotherapy business CSL Behring, where he spent 14 years.
Novavax is currently preparing to submit applications for its protein-based COVID-19 vaccine to the US Food & Drug Administration (FDA) for emergency use authorisation. It has also applied for approval in several other countries.